By Colin Kellaher
Repligen has acquired 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications for $70 million in cash.
Repligen, a Waltham, Mass., life-sciences company, on Tuesday said the acquired assets include Maverick and Maven for real-time monitoring and control of critical bioprocess parameters; Rebel, an at-line cell culture media analyzer; and ZipChip, a sample separations device used in the characterization of product quality attributes.
908 Devices, a Boston-based provider of devices for chemical analysis, said it will focus on growth of its handheld device portfolio for vital health and safety applications.
The company said the divestiture bolsters its balance sheet and pulls forward its profitability timeline, adding that it now expects to achieve positive adjusted Ebitda by the fourth quarter of this year and positive cash flow in 2026.
Trading in shares of 908 Devices was halted premarket on Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 04, 2025 07:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.